Calciscon is pioneering the development of a novel blood test for the assessment of calcification propensity, and improved cardiovascular risk management has finalised its pre-series A round. The proceeds of its CHF 0.6 million will enable the company to boost sales for its flagship product, the T50 test for patients with chronic kidney disease.
Calciscon’s pre-series A financing was raised from the lead seed investors from Switzerland and Germany. The round also includes new strategic investors from the pharmaceutical and medical laboratory sectors. The cumulated equity investment in Calciscon is now CHF 2.5M (US$ 2.7M).
The Bern-based startup is a biotech company specialising in Calcification Propensity diagnostics, an unmet medical need with a market value estimated at CHF 1.5B (US$ 1.5B). Its T50 test is a patented IVD blood test for patients with chronic kidney disease (CKD), which affects 9% of the world population. Most CKD patients still suffer and die from cardiovascular diseases (CV)with no notable outcome improvements in the last decades.
The T50 Calcification Propensity test is the first IVD test to functionally assess the tendency to calcify, revealing critical, previously unavailable information about CV risks to improve the therapy of patients. “The T50 is the long-awaited metric that provides a simple, yet complete, assessment of the calcification system allowing for personalised therapeutic intervention in the patient to slow down disease progression,” explains Andreas Pasch inventor of the T50 and founder of Calciscon. Extensive clinical evidence demonstrates the T50 is a novel independent risk factor for both CV events and death.
“The T50 test has been used by key opinion leaders across the world and by leading pharmaceutical companies for the development of new therapeutics for kidney care. The test is currently offered in Switzerland with plans to expand to neighbouring countries," explains Vincent Linder, CEO of Calciscon. "We are now giving nephrologists the opportunity to join our early access program to offer this breakthrough clinical tool to their patients.”
In parallel, Calciscon is preparing its series A financing round to launch the product to Key Opinion Leaders and early adopters in further European countries, continue to execute on its market access strategy, and upgrade the T50 instrument into an automated T50-desktop device.
(Press release)
Please login or sign up to comment.
Commenting guidelines